[ Inside the business ]

REGN stock analysis

REGN · Regeneron Pharmaceuticals, Inc.

Pharmaceutical preparations. Growing 36%.

Nothing unusual in its latest filings.

The future, in 7 questions

Priced in: 2.3× sales in 5 yrs. Evidence: sales +36% · 29¢ profit/$1.

01 What's priced in?2.3× sales in 5 yrs
Sales now$16.9B
Needed in 5 yrs$39.5B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Customer A: 50% of sales
Customer A 50%Customer B 27%Everyone else
Prepaid $750MSales +36%, speeding up
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 29¢ per $1, falling
'21'22'23'24'2529¢
Before running costs: 96% → 94%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −2.3%/yrDebt $2B
07 What could break it?Nothing flagged

✓ All clear

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth speeding up.

Sales growth +19%, +17%, then +36% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.1× the market. In the 2008 crisis it fell 35% while the market fell 51%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

55% Collaboration Revenue.

Collaboration Revenue 55% · Product 39% · Product and Service, Other 5%

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Can't score.

Not available: some of the eight inputs aren't in the company's structured filings (common for banks, insurers and companies without a cost of goods line).

Competitive advantage

10 of 10 years.

Returns beat its 6.7% cost of capital in 10 of the last 10 years. Gross margin went from 96% to 94%.

Future bets

39% on research.

$6.6B a year on R&D. $1B on equipment and buildings.

All figures from Regeneron Pharmaceuticals, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.